{"id":"fibrinolytic-once-daily","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding / Hemorrhage"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fibrinolytic drugs work by converting the inactive zymogen plasminogen into its active form, plasmin, a serine protease that degrades fibrin—the structural protein that stabilizes blood clots. This mechanism enables dissolution of existing thrombi in conditions such as acute myocardial infarction, acute ischemic stroke, and pulmonary embolism. Once-daily formulation suggests a modified-release or long-acting variant designed to improve dosing convenience.","oneSentence":"Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:29.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction"},{"name":"Acute ischemic stroke"},{"name":"Pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT06887062","phase":"PHASE2","title":"Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-21","conditions":"Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis","enrollment":60},{"nctId":"NCT07095361","phase":"PHASE4","title":"Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-09","conditions":"Pleural Infection Bacterial, Pleural Infections, Pleural Infections and Inflammations","enrollment":270},{"nctId":"NCT02777580","phase":"PHASE4","title":"STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2017-08-01","conditions":"Myocardial Infarction","enrollment":609},{"nctId":"NCT04159831","phase":"PHASE2","title":"A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions","status":"COMPLETED","sponsor":"Rein Therapeutics","startDate":"2020-09-26","conditions":"Pleural Effusion","enrollment":44},{"nctId":"NCT03873766","phase":"PHASE4","title":"Management of Pleural Space Infections","status":"COMPLETED","sponsor":"Swedish Medical Center","startDate":"2019-04-01","conditions":"Empyema, Pleural, Parapneumonic Effusion","enrollment":26},{"nctId":"NCT02227368","phase":"PHASE2","title":"Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-10-20","conditions":"Peripheral Artery Disease (PAD)","enrollment":40},{"nctId":"NCT02979561","phase":"PHASE4","title":"Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2016-10","conditions":"Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy","enrollment":200},{"nctId":"NCT00766896","phase":"PHASE4","title":"Platelet Hyperreactivity to Aspirin and Stroke","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-07","conditions":"Stroke, Cerebral Infarction, Cardiovascular Diseases","enrollment":203}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":337,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["once daily lytics","tPA once daily"],"phase":"marketed","status":"active","brandName":"Fibrinolytic once daily","genericName":"Fibrinolytic once daily","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi. Used for Acute myocardial infarction, Acute ischemic stroke, Pulmonary embolism.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}